10-Q: Propanc Biopharma Reports Q2 2026 Loss Amid R&D Focus

Sentiment:

Quarterly Report 17 February 2026 2:54 PM

Propanc Biopharma, Inc. reported a significant net loss of $7.9 million for the six months ended December 31, 2025, as it continues preclinical development of its cancer treatment candidate, PRP, and addresses going concern issues.

Delay expectedThe company accrued a registration rights penalty of $54,000 due to delayed filing and declaration of effectiveness relative to the deadlines defined in the Registration Rights Agreement in connection with the Hexstone Capital LLC Securities Purchase Agreement.

Capital raiseOn August 18, 2025, the company completed a public offering, selling 1,000,000 shares of common stock for total gross proceeds of $4,000,000 (net proceeds approximately $3.3 million).On November 4, 2025, the company completed a private placement, selling 100 shares of Series C Preferred Stock for total gross proceeds of $1,000,099 and issuing warrants to purchase up to 9,900 additional shares of Series C Preferred Stock.In February 2026, the company received aggregate gross proceeds of $500,000 from the exercise of approximately 50 Series C Warrants.The company explicitly states its dependence on debt and/or equity financing to fund ongoing operations and execute its business plan, and that it is currently seeking additional funds.

Worse than expectedNet loss significantly increased for both the three and six months ended December 31, 2025, compared to the prior year, indicating worsening financial performance.Net cash used in operating activities increased substantially, reflecting a higher cash burn rate.The company received a 'going concern' qualification from its auditors, highlighting severe financial instability and uncertainty about its ability to continue operations.Research and development expenses decreased due to cost-cutting measures, which is a negative signal for a development-stage biopharma company whose core value lies in R&D progress.The company is in default on certain loans payable, indicating liquidity challenges and potential for further financial penalties.

Summary

The company reported no revenues for the three and six months ended December 31, 2025, and 2024.
Net loss for the three months ended December 31, 2025, was $(3,091,394), a significant increase from $(430,183) in the prior year.
Net loss for the six months ended December 31, 2025, was $(7,929,132), compared to $(784,493) for the same period in 2024.
The accumulated deficit as of December 31, 2025, reached $134,482,898.
Cash on hand as of December 31, 2025, was $561,237.
Net cash used in operating activities for the six months ended December 31, 2025, was $(2,938,207).
A public offering completed on August 18, 2025, generated gross proceeds of $4,000,000 from the sale of 1,000,000 common shares, resulting in approximately $3.3 million in net proceeds.
A private placement on November 4, 2025, raised gross proceeds of $1,000,099 from the sale of 100 shares of Series C Preferred Stock and the issuance of warrants for 9,900 additional shares.
The company filed two provisional patents on December 1, 2025, for new methods to treat resistant cancer and fibrosis.
Key research findings on the impact of proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts were published in Scientific Reports on December 22, 2025.
New provisional patent applications were filed on January 20, 2026, for producing a fully synthetic recombinant version of PRP (Rec-PRP), and on January 27, 2026, for innovative proenzyme formulations addressing stability and storage.
Administration expenses increased substantially to $8,226,747 for the six months ended December 31, 2025, primarily due to stock-based consulting and other professional fees.
Research and development expenses decreased to $80,162 for the six months ended December 31, 2025, attributed to cost-cutting measures.
Management and independent auditors have raised substantial doubt about the company's ability to continue as a going concern.
Material weaknesses in internal control over financial reporting were identified, including a lack of written documentation and insufficient segregation of duties.
A legal proceeding was initiated by Helena Partners, Inc. on December 9, 2025, seeking $15,000 deal deposit and $250,000 break fees for an alleged breach of an engagement agreement.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly concerning report due to the substantial increase in net losses, significant cash burn, and the explicit 'going concern' warning, despite recent capital raises and patent activity. The reduction in R&D due to funding issues is a major red flag for a development-stage biopharma.

Positives

Successfully completed a public offering on August 18, 2025, raising approximately $3.3 million in net proceeds.
Successfully completed a private placement on November 4, 2025, raising $1,000,099 in gross proceeds from Series C Preferred Stock and warrants.
Filed two new provisional patents on December 1, 2025, detailing methods to treat resistant cancer and fibrosis, indicating ongoing innovation.
Published key research findings in the peer-reviewed journal Scientific Reports on December 22, 2025, enhancing scientific credibility for PRP.
Filed a new provisional patent application on January 20, 2026, for a fully synthetic recombinant version of PRP (Rec-PRP), which could offer significant regulatory and commercial advantages.
Filed another new provisional patent application on January 27, 2026, focusing on innovative formulations to improve stability, storage, and global transport of proenzymes.
Repaid several promissory notes and loans payable, including those previously in default, reducing some debt obligations.

Negatives

Reported a significant increase in net loss to $(3,091,394) for the three months and $(7,929,132) for the six months ended December 31, 2025, compared to the prior year.
Accumulated deficit reached $134,482,898 as of December 31, 2025, indicating substantial historical losses.
Net cash used in operating activities increased substantially to $(2,938,207) for the six months ended December 31, 2025.
Management and independent auditors have raised substantial doubt about the company's ability to continue as a going concern due to lack of revenues and significant losses.
Administration expenses surged to $8,226,747 for the six months ended December 31, 2025, primarily driven by increased stock-based consulting and other professional fees.
Research and development expenses decreased due to cost-cutting measures, which may hinder the progress of core product development.
The company was in default on certain loans payable as of December 31, 2025.
A legal proceeding was initiated by Helena Partners, Inc. seeking $265,000 in fees, adding to financial and operational uncertainty.
A deemed dividend of $932,246 was recognized upon the issuance of Series C Preferred Stock, reducing income available to common stockholders.
Accrued a registration rights penalty of $54,000 payable in common stock due to delayed filing related to the Hexstone Capital LLC Securities Purchase Agreement.

Risks

Substantial doubt exists about the company's ability to continue as a going concern for at least twelve months due to no revenues, significant net losses, and net cash used in operations.
The company is highly dependent on obtaining adequate future financing (debt and/or equity) to fund development activities and operations, with no assurance such financing will be available on reasonable terms or at all.
Future equity or convertible debt financing may cause substantial dilution for existing stockholders.
The company's ability to continue as a going concern is dependent on its ability to further develop and execute its business plan.
Products are not currently approved for market, and patent costs are expensed immediately until market authorization is received, indicating a long path to commercialization.
A pending complaint from Helena Partners, Inc. alleges breach of an engagement agreement and seeks $265,000 in fees, which could result in an adverse financial impact.
Material weaknesses in internal control over financial reporting exist, including a lack of written documentation for policies and procedures and insufficient segregation of duties, which could lead to financial misstatements.
The company is in default on certain loans payable, which could trigger acceleration clauses or other penalties and further strain liquidity.
Fluctuations in currency exchange rates, particularly between the Australian dollar and USD, can impact financial results due to foreign operations.
Cash is maintained in uninsured Australian bank accounts, posing a concentration of credit risk.
100% of the company's receivables are related to GST tax reimbursements, indicating a lack of diversified revenue streams.
The independent registered public accounting firm's going concern qualification might make it substantially more difficult to raise capital.

Future Outlook

The company anticipates establishing global markets for its technologies, with its lead product candidate, PRP, currently in the preclinical phase of development. It plans to capture and protect additional patentable subject matter by filing more patent applications as PRP advances. Further research and development collaborations are under negotiation with the University of Jaen and other contract research organizations, contingent on available working capital. Management believes a fully synthetic recombinant version of PRP (Rec-PRP) holds significant regulatory and commercial potential for global distribution, and a 12-month addendum for additional experiments with the University of Jaen is being negotiated.

Management Comments

"Management believes a fully synthetic recombinant version of PRP would have tremendous implications from a regulatory perspective, but also a practical, commercial benefit for global distribution."
"The overall decrease in research and development expenses is primarily related to our cost-cutting measures due to insufficient working capital funding."
"Further research and development collaborations are currently under negotiation with the University of Jan and other contract research organizations in preparation for upcoming available working capital for future research and development expenses."

Industry Context

StockSavvy.ai notes that Propanc Biopharma's focus on developing non-toxic, long-term therapies for cancer survivors and preventing recurrence addresses a critical unmet need in oncology, particularly given the high global mortality rates and the emergence of treatment resistance. The exploration of pro-enzymes and a fully synthetic recombinant version of PRP aligns with broader industry trends towards targeted therapies and biomanufacturing efficiency. The publication in Scientific Reports lends scientific credibility to their preclinical findings in the competitive cancer research landscape, which is crucial for attracting future investment and partnerships.

Comparison to Industry Standards

Propanc Biopharma's preclinical stage and significant R&D expenses, coupled with operating losses, are typical for early-stage biopharma companies, comparable to firms like **Relay Therapeutics (RLAY)** or **Denali Therapeutics (DNLI)** in their early development phases.
The substantial increase in administrative expenses, particularly stock-based compensation, appears higher than typical for companies of similar size and stage, potentially indicating aggressive compensation strategies or a heavy reliance on equity for services, which could be a concern for capital efficiency.
The 'going concern' qualification is a common challenge for early-stage biotech firms, but it underscores the urgent need for further capital, a hurdle faced by many small biotechs, such as **Avalo Therapeutics (AVTX)** or **Veru Inc. (VERU)**, which often struggle with funding continuity.
The company's patent portfolio, with 85 granted and 7 pending, is robust for a preclinical company, demonstrating a strong intellectual property foundation comparable to early-stage innovators like **Moderna (MRNA)** in its foundational years or smaller biotech firms like **Fate Therapeutics (FATE)**, which heavily rely on IP protection for future value.
The net cash used in operations ($2.9 million for six months) is within the expected range for preclinical companies, though the magnitude of the net loss ($7.9 million for six months) is substantial, indicating a high burn rate relative to its current stage of development, which is a common characteristic among high-growth potential but pre-revenue biotechs.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Internal Control Weaknesses	Identified material weaknesses in internal control over financial reporting, including a lack of written documentation for internal control policies and procedures and insufficient segregation of duties within accounting functions.	2025-12-31	These weaknesses raise a reasonable possibility that a material misstatement of financial statements will not be prevented or detected on a timely basis, potentially affecting financial reporting reliability and investor confidence.
Planned Improvements to Internal Controls	Plans to establish an audit committee of the board of directors (comprised of at least two independent directors), add experienced accounting and financial personnel, and retain third-party consultants to review internal controls and recommend improvements. The CFO's role is also being defined as full-time.		These actions are intended to mitigate identified material weaknesses and improve the effectiveness of disclosure controls and internal controls over financial reporting, although success is not guaranteed.
Voting Power Concentration	The CEO, Mr. Nathanielsz, directly beneficially owns one share of Series B Preferred Stock, which confers upon him a majority vote, including regarding authorization of additional common shares and/or the authorization of a reverse split of the stock.		This concentration of voting power gives the CEO significant control over key corporate actions, potentially limiting the influence of common stockholders on such decisions.

Legal Proceedings

On December 9, 2025, the company was served with a complaint filed in the Superior Court of the State Delaware by Helena Partners, Inc. (Helena).
Helena alleges breach of an engagement agreement dated August 3, 2025, between the company and Helena.
Helena argues that the company owes a $15,000 deal deposit fee for entering into the Engagement Agreement and a $250,000 break fee for not completing an equity financing with Helena.
On January 15, 2026, the company filed an answer to the Complaint and intends to vigorously defend the action.

Related Party Transactions

The company leases its principal executive offices from North Horizon Pty Ltd., a related party owned by Mr. Nathanielsz (CEO, CFO, director) and his wife. The monthly rent is $3,300 AUD ($2,127 USD), and total rent payable was $87,604 USD as of December 31, 2025.
An institutional investor affiliated with Josef Zelinger (a director) loaned the company an aggregate of $120,000 AUD ($78,249 USD) between July 3, 2025, and August 14, 2025, which was fully repaid on August 19, 2025.
The company repaid certain loans payable to a related party with an aggregate principal amount of $150,808 USD and accrued interest of $3,994 USD on August 21, 2025.
Total remaining balance of loans payable related parties, net of discount, amounted to $472,083 as of December 31, 2025.
Mr. Nathanielsz, CEO, CFO, and director, has an employment agreement with an annual base salary of $600,000 AUD ($414,900 USD).
Dr. Kenyon, Chief Scientific Officer and director, has a services agreement with an annual salary of $54,000 AUD ($41,580 USD) and an annual director's fee of $45,000 USD starting October 1, 2025.
Sylvia Nathanielsz, Mr. Nathanielsz's wife, is a non-executive, part-time employee with an annual salary of $120,000 AUD ($80,904 USD).
Total accrued salaries of $148,549 USD and employee benefit liability of $703,190 were recorded as of December 31, 2025.
Intercompany loans made by the parent to its subsidiary, Propanc PTY LTD, have not been repaid and are not expected to be repaid in the foreseeable future.

Stakeholder Impact

**Shareholders**: Face significant dilution from recent and potential future equity raises. The substantial increase in net loss and the 'going concern' warning could negatively impact share value. The ongoing legal proceeding adds further uncertainty.
**Employees**: The company has a significant employee benefit liability of $703,190. Cost-cutting measures, particularly in R&D, could impact job security and morale, potentially affecting scientific talent retention.
**Creditors**: The company is in default on some loans, increasing risk for these creditors. While some debt has been repaid, the overall weak financial health and 'going concern' status pose a risk to remaining creditors.
**Customers (future)**: As a preclinical stage company, there is no direct customer impact yet. However, the reduction in R&D spending due to insufficient working capital could delay the development and eventual availability of its cancer treatments.
**Suppliers**: Although not explicitly detailed, the company's liquidity issues and 'going concern' status could lead to potential delays in payments to suppliers, impacting business relationships.

Next Steps

Obtain adequate financing to fulfill development activities and support ongoing operations.
Seek additional sources of suitable and adequate financing to address liquidity concerns.
Further develop and execute on the business plan to achieve commercial viability.
Establish an audit committee of the board of directors to improve corporate governance.
Add experienced accounting and financial personnel to strengthen internal controls.
Retain third-party consultants to review internal controls and recommend improvements.
Define the chief financial officer's role as full-time to enhance financial oversight.
Vigorously defend the legal action initiated by Helena Partners, Inc. to mitigate potential financial liabilities.
Negotiate further research and development collaborations with the University of Jaen and other contract research organizations.
File provisional patents detailing new methods to treat resistant cancer and fibrosis in key global jurisdictions.
Advance the lead product candidate, PRP, through various stages of development towards market approval.
Negotiate a subsequent 12-month addendum for additional experiments with the University of Jaen.
Continue efforts to reduce par value or conduct a reverse split of common stock if conversion prices fall below par value, as per financing agreements.

Key Dates

Date	Description
2007-10-15	Propanc PTY LTD originally formed in Melbourne, Victoria, Australia.
2010-11-23	Propanc Health Group Corporation incorporated in Delaware.
2011-01-01	Propanc Health Group Corporation acquired all outstanding shares of Propanc PTY LTD.
2012-06-01	Company and the UK University entered into an assignment and amendment whereby the Company assumed full ownership of the intellectual property.
2015-02-25	Company and Mr. Nathanielsz entered into an employment agreement.
2016-05-05	Company entered into an agreement for the lease of its principal executive offices with North Horizon Pty Ltd.
2016-07-22	Company formed a wholly-owned subsidiary, Propanc (UK) Limited.
2017-04-20	Company changed its name to Propanc Biopharma, Inc.
2018-02-01	Mrs. Nathanielsz's annual salary of $120,000 AUD became effective.
2018-03-16	Board of directors approved an increase of Mr. Nathanielsz's annual base salary to $400,000 AUD.
2018-09-13	Company entered into a two-year collaboration agreement with the University of Jaen.
2019-05-14	Company entered into an Amended and Restated Employment Agreement with Mr. Nathanielsz and an Amended and Restated Services Agreement with Dr. Kenyon.
2019-10-03	Company entered into a securities purchase agreement with Crown Bridge Partners, LLC.
2020-10-01	Company entered into another two-year collaboration agreement with the University of Jaen.
2020-11-01	First installment payment of 5,000 Euros to University of Jaen.
2021-03-01	Second installment payment of 5,000 Euros to University of Jaen.
2021-08-12	Board approved a bonus of $177,840 USD for Mr. Nathanielsz.
2021-12-01	Third installment payment of 10,000 Euros to University of Jaen.
2022-05-04	Company entered into a three-year lease agreement with North Horizon Pty Ltd.
2022-07-27	Company entered into a two-year research agreement with the University of Jaen.
2022-08-01	Board approved an increase of Mr. Nathanielsz's annual base salary to $600,000 AUD.
2022-08-01	First installment payment of 18,200 Euros to University of Jaen.
2022-09-01	Fourth installment payment of 10,000 Euros to University of Jaen.
2022-10-26	Company entered into an Amended and Restated Employment Agreement with Mr. Nathanielsz, effective July 1, 2022.
2022-12-01	Third installment payment of 7,000 Euros to University of Jaen.
2023-03-01	Fourth installment payment of 10,000 Euros to University of Jaen.
2023-07-01	Fifth installment payment of 10,000 Euros to University of Jaen.
2023-07-05	Company and an institutional investor affiliated with Josef Zelinger entered into a letter agreement for a $230,000 AUD loan.
2023-08-15	Company issued a 10% original issue discount promissory note to an institutional investor.
2023-08-23	Company entered into a securities purchase agreement with GS Capital Partners, LLC.
2023-10-12	Company entered into a securities purchase agreement with GS Capital Partners, LLC.
2023-11-29	1800 Diagonal Lending (formerly Sixth Street Lending) Securities Purchase Agreement.
2023-12-08	Company entered into a securities purchase agreement with ONE44 Capital.
2024-01-01	Board approved a bonus of $150,000 AUD for Mr. Nathanielsz.
2024-03-05	Company entered into a securities purchase agreement with 104 LLC.
2024-04-12	Company entered into a securities purchase agreement with GS Capital Partners, LLC.
2024-05-07	August 2023 Lender notified the Company of waiver of default repayment and extension of promissory note maturity to December 31, 2024.
2024-05-24	Company entered into a 15% promissory note with 1800 Diagonal Lending, LLC.
2024-06-10	Company entered into a 15% promissory note with 1800 Diagonal Lending, LLC.
2024-06-20	Company entered into a securities purchase agreement with 104 LLC.
2024-08-01	Company entered into a loan agreement with an institutional investor affiliated with Josef Zelinger for $150,000 AUD.
2024-08-02	Company entered into a securities purchase agreement with GS Capital Partners, LLC.
2024-09-20	Company entered into a securities purchase agreement with GS Capital Partners, LLC.
2024-12-03	Company entered into a loan agreement with an institutional investor affiliated with Josef Zelinger for $175,000 AUD.
2024-12-04	Company entered into a 15% promissory note with Red Road Holdings.
2024-12-13	Company entered into a securities purchase agreement with Geebis Consulting, LLC.
2025-01-23	Company entered into a Debt Exchange Agreement with a former director.
2025-01-31	Company entered into a securities purchase agreement with 1800 Diagonal.
2025-02-05	Company entered into Debt Exchange Agreements with two investors.
2025-02-07	Company entered into a securities purchase agreement with GS Capital Partners, LLC.
2025-03-11	Company entered into a securities purchase agreement with GS Capital Partners, LLC.
2025-03-25	Company entered into a securities purchase agreement with 1800 Diagonal.
2025-04-12	Company entered into a loan agreement with an institutional investor affiliated with Josef Zelinger for $63,188 AUD.
2025-04-15	Company entered into a securities purchase agreement with GS Capital Partners, LLC.
2025-05-04	Company entered into a one-year lease agreement with North Horizon Pty Ltd.
2025-05-07	Company entered into a Maturity Extension Agreement with the August 2023 Lender, extending maturity to June 15, 2025.
2025-05-07	Company entered into a promissory note agreement with an institutional investor for $90,000.
2025-06-02	Company entered into a promissory note agreement with an institutional investor for $60,000.
2025-06-12	Company entered into a securities purchase agreement with Geebis Consulting, LLC.
2025-06-13	Company entered into a loan agreement with an institutional investor affiliated with Josef Zelinger for $15,000 AUD.
2025-06-13	Company entered into a 15% promissory note with 1800 Diagonal Lending, LLC.
2025-06-30	End of fiscal year 2025.
2025-07-03	Start of period for loans from an institutional investor affiliated with Josef Zelinger ($120,000 AUD aggregate).
2025-07-18	Company entered into a promissory note agreement with an investor for $82,500.
2025-07-22	Company entered into a securities purchase agreement with 1800 Diagonal.
2025-08-03	Engagement agreement with Helena Partners, Inc. (subject of legal dispute).
2025-08-14	End of period for loans from an institutional investor affiliated with Josef Zelinger ($120,000 AUD aggregate).
2025-08-14	Company entered into an underwriting agreement with D. Boral Capital, LLC for a public offering.
2025-08-15	Company and a consultant agreed to enter into a three-month consulting agreement.
2025-08-18	Public offering completed, selling 1,000,000 shares of common stock.
2025-08-19	Company fully repaid several promissory notes and loans payable.
2025-08-21	Company fully repaid certain loans payable to a related party.
2025-08-24	Company incurred consulting fees for management advisory services.
2025-08-30	Company amended a consulting agreement to provide additional compensation in common stock.
2025-09-01	First issuance of common stock under amended consulting agreement.
2025-09-25	Company and a consultant agreed to enter into a one-year Advisory Agreement.
2025-10-01	Dr. Kenyon's annual directors fee of $45,000 USD began.
2025-11-04	Company completed a private placement with Hexstone Capital LLC, selling Series C Preferred Stock and warrants.
2025-12-01	Two provisional patents filed detailing new methods to treat resistant cancer and fibrosis.
2025-12-09	Company was served with a complaint by Helena Partners, Inc.
2025-12-22	Company and its joint research partners published key findings in Scientific Reports.
2025-12-31	End of the quarterly reporting period.
2026-01-07	Company entered into an Exchange Agreement with Crown Bridge, issuing common stock for outstanding loan balance and accrued interest.
2026-01-15	Company filed an answer to the complaint from Helena Partners, Inc.
2026-01-20	New provisional patent application filed for methods of producing trypinsogen and chymotrypsinogen with IP Australia.
2026-01-27	Company filed a new provisional patent application focusing on innovative formulations of pancreatic proenzymes.
2026-02-16	Date for shares of common stock issued and outstanding (15,859,280 shares).
2026-02-17	Filing date of the Form 10-Q.
2026-02-28	Company received aggregate gross proceeds of $500,000 from the exercise of approximately 50 Series C Warrants.

Recommendation

strong sell

The company faces severe financial distress, evidenced by a substantial increase in net losses, significant cash burn, and an explicit 'going concern' qualification from its auditors. While recent capital raises provide temporary relief, the underlying operational issues, including reduced R&D due to insufficient working capital and ongoing defaults on debt, indicate a highly precarious financial position. The legal dispute further adds to the uncertainty. For a development-stage biopharma, a slowdown in R&D is a critical negative signal. The risk of further dilution and potential bankruptcy is high, making this a strong sell for investors.

Keywords

Cancer treatment, Biopharma, Preclinical development, PRP, Proenzymes, Oncology, Pancreatic cancer, Fibrosis, Patents, SEC filing, 10-Q, Going concern, Equity financing, Convertible debt, Stock-based compensation, Research and development, Financial results, Biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.